Jeff Yass’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12M | Sell |
1,195,651
-1,619,653
| -58% | -$14.6M | ﹤0.01% | 3107 |
|
|
2026
Q1 | $26.8M | Buy |
2,815,304
+2,143,611
| +319% | +$16.6M | ﹤0.01% | 1876 |
|
|
2025
Q4 | $5.24M | Buy |
671,693
+425,932
| +173% | +$3.08M | ﹤0.01% | 3942 |
|
|
2025
Q3 | $1.87M | Sell |
245,761
-158,770
| -39% | -$1.32M | ﹤0.01% | 5941 |
|
|
2025
Q2 | $3.62M | Buy |
404,531
+7,669
| +2% | +$71.4K | ﹤0.01% | 4592 |
|
|
2025
Q1 | $2.98M | Buy |
396,862
+171,162
| +76% | +$1.38M | ﹤0.01% | 4667 |
|
|
2024
Q4 | $1.7M | Sell |
225,700
-9,166
| -4% | -$69.6K | ﹤0.01% | 5679 |
|
|
2024
Q3 | $1.78M | Sell |
234,866
-41,485
| -15% | -$315K | ﹤0.01% | 5508 |
|
|
2024
Q2 | $1.71M | Sell |
276,351
-840,606
| -75% | -$4.64M | ﹤0.01% | 5403 |
|
|
2024
Q1 | $5.67M | Buy |
1,116,957
+782,090
| +234% | +$4.4M | ﹤0.01% | 3447 |
|
|
2023
Q4 | $2.01M | Buy |
334,867
+15,250
| +5% | +$88.4K | ﹤0.01% | 5340 |
|
|
2023
Q3 | $2.26M | Sell |
319,617
-98,664
| -24% | -$709K | ﹤0.01% | 4885 |
|
|
2023
Q2 | $2.94M | Sell |
418,281
-152,426
| -27% | -$1.22M | ﹤0.01% | 4402 |
|
|
2023
Q1 | $4.76M | Buy |
570,707
+36,467
| +7% | +$351K | ﹤0.01% | 3543 |
|
|
2022
Q4 | $6.13M | Sell |
534,240
-413,189
| -44% | -$5.15M | ﹤0.01% | 2920 |
|
|
2022
Q3 | $11.9M | Sell |
947,429
-74,947
| -7% | -$965K | ﹤0.01% | 1937 |
|
|
2022
Q2 | $10.8M | Sell |
1,022,376
-217,375
| -18% | -$2.24M | ﹤0.01% | 2110 |
|
|
2022
Q1 | $20.2M | Sell |
1,239,751
-756,233
| -38% | -$12.1M | ﹤0.01% | 1722 |
|
|
2021
Q4 | $27.6M | Buy |
1,995,984
+263,742
| +15% | +$3.49M | ﹤0.01% | 1544 |
|
|
2021
Q3 | $24.9M | Buy |
1,732,242
+90,292
| +5% | +$1.42M | ﹤0.01% | 1751 |
|
|
2021
Q2 | $26M | Sell |
1,641,950
-452,495
| -22% | -$6.15M | ﹤0.01% | 1761 |
|
|
2021
Q1 | $21.3M | Buy |
2,094,445
+50,462
| +2% | +$520K | ﹤0.01% | 1795 |
|
|
2020
Q4 | $15.2M | Buy |
2,043,983
+726,520
| +55% | +$3.75M | ﹤0.01% | 2024 |
|
|
2020
Q3 | $4.53M | Sell |
1,317,463
-102,524
| -7% | -$439K | ﹤0.01% | 3187 |
|
|
2020
Q2 | $6.77M | Buy |
1,419,987
+1,029,620
| +264% | +$4.11M | ﹤0.01% | 2612 |
|
|
2020
Q1 | $781K | Buy |
390,367
+278,842
| +250% | +$768K | ﹤0.01% | 5940 |
|
|
2019
Q4 | $385K | Sell |
111,525
-33,363
| -23% | -$83.9K | ﹤0.01% | 7506 |
|
|
2019
Q3 | $415K | Sell |
144,888
-309,811
| -68% | -$964K | ﹤0.01% | 7677 |
|
|
2019
Q2 | $1.72M | Buy |
+454,699
| New | +$2.74M | ﹤0.01% | 4470 |
|
|
2017
Q4 | – | Sell |
-38,923
| Closed | -$189K | – | 9232 |
|
|
2017
Q3 | $204K | Buy |
+38,923
| New | +$199K | ﹤0.01% | 7984 |
|
|
2017
Q2 | – | Sell |
-60,589
| Closed | -$369K | – | 9181 |
|
|
2017
Q1 | $509K | Sell |
60,589
-309,827
| -84% | -$2.16M | ﹤0.01% | 6455 |
|
|
2016
Q4 | $2.35M | Buy |
370,416
+257,615
| +228% | +$1.34M | ﹤0.01% | 3731 |
|
|
2016
Q3 | $497K | Buy |
112,801
+25,561
| +29% | +$102K | ﹤0.01% | 6057 |
|
|
2016
Q2 | $248K | Sell |
87,240
-42,174
| -33% | -$131K | ﹤0.01% | 7269 |
|
|
2016
Q1 | $366K | Sell |
129,414
-29,846
| -19% | -$132K | ﹤0.01% | 6925 |
|
|
2015
Q4 | $1.64M | Buy |
159,260
+7,020
| +5% | +$69.8K | ﹤0.01% | 4431 |
|
|
2015
Q3 | $1.74M | Buy |
152,240
+122,312
| +409% | +$1.63M | ﹤0.01% | 4550 |
|
|
2015
Q2 | $447K | Buy |
29,928
+16,014
| +115% | +$182K | ﹤0.01% | 7841 |
|
|
2015
Q1 | $126K | Sell |
13,914
-70,312
| -83% | -$728K | ﹤0.01% | 8879 |
|
|
2014
Q4 | $1.02M | Buy |
+84,226
| New | +$930K | ﹤0.01% | 5834 |
|
|
2014
Q3 | – | Sell |
-58,342
| Closed | -$715K | – | 9414 |
|
|
2014
Q2 | $744K | Sell |
58,342
-216,325
| -79% | -$2.1M | ﹤0.01% | 6675 |
|
|
2014
Q1 | $2.91M | Buy |
+274,667
| New | +$2.93M | ﹤0.01% | 3703 |
|
|
2013
Q3 | – | Sell |
-325,300
| Closed | -$1.65M | – | 8382 |
|
|
2013
Q2 | $504K | Buy |
+325,300
| New | +$561K | ﹤0.01% | 6022 |
|
Other funds holding BCRX
RCM
DM
TCM
PA
JT
VPC
Jeff Yass's BCRX Position: Q2 2026 in Review
Jeff Yass reduced its BioCryst Pharmaceuticals (BCRX) stake by 58% in Q2 2026, selling an estimated $14.6M and leaving 1,195,651 shares worth $12M. The position accounts for ﹤0.01% of the portfolio, ranked #3107.
Jeff Yass first reported a position in BCRX in Q2 2013 and has held it in 43 quarters since. The position peaked at $27.6M in Q4 2021. 316 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.
- Jeff Yass held 1,195,651 shares of BioCryst Pharmaceuticals worth $12M as of Q2 2026.
- Jeff Yass sold 1,619,653 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $14.6M.
- BioCryst Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #3107 holding.
- Jeff Yass first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
- Jeff Yass's BioCryst Pharmaceuticals position peaked at $27.6M in Q4 2021.
- 316 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.